Jennifer Lachey - 15 Jul 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
15 Jul 2022
Net transactions value
-$1,367,210
Form type
4
Filing time
19 Jul 2022, 16:40:13 UTC
Previous filing
15 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $13,810 +46,034 +48% $0.3000* 141,134 15 Jul 2022 Direct
transaction KROS Common Stock Sale $1,381,020 -46,034 -33% $30.00 95,100 15 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -46,034 -84% $0.000000 8,755 15 Jul 2022 Common Stock 46,034 $0.3000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.